Alzheimer's & Dementia: The Journal of the Alzheimer's Association
Volume 2, Issue 1 , Pages 43-55 , January 2006

Synaptic targeting by Aβ oligomers (ADDLS) as a basis for memory loss in early Alzheimer’s disease

References 

  1. Small GW , Rabins PV , Barry PP , Buckholtz NS , DeKosky ST , Ferris SH , et al.   Diagnosis and treatment of Alzheimer disease and related disorders. Consensus statement of the American Association for Geriatric Psychiatry, the Alzheimer’s Association, and the American Geriatrics Society . JAMA . 1997;278(16):1363–1371
  2. Roman GC , Rogers SJ . Donepezil (A clinical review of current and emerging indications) . Expert Opin Pharmacother . 2004;5(1):161–180
  3. Witt A , Macdonald N , Kirkpatrick P . Memantine hydrochloride . Nat Rev Drug Discov . 2004;3(2):109–110
  4. Marx J . Alzheimer’s debate boils over . Science . 1992;257(5075):1336–1338
  5. Pike CJ , Burdick D , Walencewicz AJ , Glabe CG , Cotman CW . Neurodegeneration induced by beta-amyloid peptides in vitro (the role of peptide assembly state) . J Neurosci . 1993;13(4):1676–1687
  6. Lorenzo A , Yankner BA . Beta-amyloid neurotoxicity requires fibril formation and is inhibited by congo red . Proc Natl Acad Sci U S A . 1994;91(25):12243–12247
  7. Klein WL . Aβ toxicity in Alzheimer’s disease . In:  Chesselet MF editors. Molecular mechanisms of neurodegenerative diseases . Totowa, New Jersey: Humana Press, Inc; 2001;p. 1–49
  8. Lambert MP , Stevens G , Sabo S , Barber K , Wang G , Wade W , et al.   Beta/A4–evoked degeneration of differentiated SH-SY5Y human neuroblastoma cells . J Neurosci Res . 1994;39(4):377–385
  9. Busciglio J , Lorenzo A , Yeh J , Yankner BA . beta-amyloid fibrils induce tau phosphorylation and loss of microtubule binding . Neuron . 1995;14(4):879–888
  10. Rapoport M , Dawson HN , Binder LI , Vitek MP , Ferreira A . Tau is essential to beta-amyloid-induced neurotoxicity . Proc Natl Acad Sci U S A . 2002;99(9):6364–6369
  11. Zhang C , Lambert MP , Bunch C , Barber K , Wade WS , Krafft GA , et al.   Focal adhesion kinase expressed by nerve cell lines shows increased tyrosine phosphorylation in response to Alzheimer’s A beta peptide . J Biol Chem . 1994;269(41):25247–25250
  12. Zhang C , Qiu HE , Krafft GA , Klein WL . A beta peptide enhances focal adhesion kinase/Fyn association in a rat CNS nerve cell line . Neurosci Lett . 1996;211(3):187–190
  13. Lesort M , Jope RS , Johnson GV . Insulin transiently increases tau phosphorylation (Involvement of glycogen synthase kinase-3beta and Fyn tyrosine kinase) . J Neurochem . 1999;72(2):576–584
  14. Hardy JA , Higgins GA . Alzheimer’s disease (the amyloid cascade hypothesis) . Science . 1992;256(5054):184–185
  15. Schenk D , Barbour R , Dunn W , Gordon G , Grajeda H , Guido T , et al.   Immunization with amyloid-beta attenuates Alzheimer-disease-like pathology in the PDAPP mouse . Nature . 1999;400(6740):173–177
  16. Dodart JC , Bales KR , Gannon KS , Greene SJ , DeMattos RB , Mathis C , et al.   Immunization reverses memory deficits without reducing brain Aβ burden in Alzheimer’s disease model . Nat Neurosci . 2002;5(5):452–457
  17. Kotilinek LA , Bacskai B , Westerman M , Kawarabayashi T , Younkin L , Hyman BT , et al.   Reversible memory loss in a mouse transgenic model of Alzheimer’s disease . J Neurosci . 2002;22(15):6331–6335
  18. Katzman R , Terry R , DeTeresa R , Brown T , Davies P , Fuld P , et al.   Clinical, pathological, and neurochemical changes in dementia (a subgroup with preserved mental status and numerous neocortical plaques) . Ann Neurol . 1988;23(2):138–144
  19. Terry RD . The neuropathology of Alzheimer disease and the structural basis of its cognitive alterations . In:  Terry RD ,  Katzman R ,  Bick KL ,  Sisodia SS editor. Alzheimer disease . Philadelphia, PA: Lippincott Williams, & Wilkins; 1999;p. 187–206
  20. Neve RL , Robakis NK . Alzheimer’s disease (A re-examination of the amyloid hypothesis) . Trends Neurosci . 1998;21(1):15–19
  21. Sadowski M , Pankiewicz J , Scholtzova H , Ji Y , Quartermain D , Jensen CH , et al.   Amyloid-beta deposition is associated with decreased hippocampal glucose metabolism and spatial memory impairment in APP/PS1 mice . J Neuropathol Exp Neurol . 2004;63(5):418–428
  22. Oda T , Pasinetti GM , Osterburg HH , Anderson C , Johnson SA , Finch CE . Purification and characterization of brain clusterin . Biochem Biophys Res Commun . 1994;204(3):1131–1136
  23. Oda T , Wals P , Osterburg HH , Johnson SA , Pasinetti GM , Morgan TE , et al.   Clusterin (apoJ) alters the aggregation of amyloid beta-peptide (A beta 1-42) and forms slowly sedimenting A beta complexes that cause oxidative stress . Exp Neurol . 1995;136(1):22–31
  24. Lambert MP , Barlow AK , Chromy BA , Edwards C , Freed R , Liosatos M , et al.   Diffusible, nonfibrillar ligands derived from Aβ1-42 are potent central nervous system neurotoxins . Proc Natl Acad Sci U S A . 1998;95(11):6448–6453
  25. Stine WB , Snyder SW , Ladror US , Wade WS , Miller MF , Perun TJ , et al.   The nanometer-scale structure of amyloid-beta visualized by atomic force microscopy . J Protein Chem . 1996;15(2):193–203
  26. Klein WL . Aβ toxicity in Alzheimer’s disease (Globular oligomers (ADDLs) as new vaccine and drug targets) . Neurochem Int . 2002;41(5):345
  27. Lambert MP , Viola KL , Chromy BA , Chang L , Morgan TE , Yu J , et al.   Vaccination with soluble Aβ oligomers generates toxicity-neutralizing antibodies . J Neurochem . 2001;79(3):595–605
  28. Chromy BA , Nowak RJ , Lambert MP , Viola KL , Chang L , Velasco PT , et al.   Self-assembly of Aβ(1-42) into globular neurotoxins . Biochemistry . 2003;42(44):12749–12760
  29. Levine H . Soluble multimeric Alzheimer beta(1-40) pre-amyloid complexes in dilute solution . Neurobiol Aging . 1995;16(5):755–764
  30. Bitan G , Kirkitadze MD , Lomakin A , Vollers SS , Benedek GB , Teplow DB . Amyloid beta -protein (Aβ) assembly (Aβ 40 and Aβ 42 oligomerize through distinct pathways) . Proc Natl Acad Sci U S A . 2003;100(1):330–335
  31. Levine H . Alzheimer’s beta-peptide oligomer formation at physiologic concentrations . Anal Biochem . 2004;335(1):81–90
  32. Chang L , Bakhos L , Wang Z , Venton DL , Klein WL . Femtomole immunodetection of synthetic and endogenous Amyloid-β oligomers and its application to Alzheimer’s Disease drug candidate screening . J Mol Neurosci . 2003;20(3):305–313
  33. Huang X , Atwood CS , Moir RD , Hartshorn MA , Tanzi RE , Bush AI . Trace metal contamination initiates the apparent auto-aggregation, amyloidosis, and oligomerization of Alzheimer’s Aβ peptides . J Biol Inorg Chem . 2004;9(8):954–960
  34. Boutaud O, Montine TJ, Chang L, Klein WL, Oates JA. PGH2-derived levuglandin adducts increase the neurotoxicity of amyloid β1-42. J Biol Chem (in press).
  35. Wang HW , Pasternak JF , Kuo H , Ristic H , Lambert MP , Chromy B , et al.   Soluble oligomers of beta amyloid (1-42) inhibit long-term potentiation but not long-term depression in rat dentate gyrus . Brain Res . 2002;924(2):133–140
  36. Gong Y , Chang L , Viola KL , Lacor PN , Lambert MP , Finch CE , et al.   Alzheimer’s disease-affected brain (Presence of oligomeric Aβ ligands (ADDLs) suggests a molecular basis for reversible memory loss) . Proc Natl Acad Sci U S A . 2003;100(18):10417–10422
  37. Lacor PN , Buniel MC , Chang L , Fernandez SJ , Gong Y , Viola KL , et al.   Synaptic targeting by Alzheimer’s-related amyloid beta oligomers . J Neurosci . 2004;24(45):10191–10200
  38. Sheng M , Lee SH . AMPA receptor trafficking and the control of synaptic transmission . Cell . 2001;105(7):825–828
  39. Lacor PN , Buniel MC , Klein WL . ADDLs (Aβ oligomers) alter structure and function of synaptic spines . 2004; 2004 Abstract Viewer/Itinerary Planner Washington, DC: Society for Neuroscience[Online], Program No. 218.3
  40. Lacor PN , Sanz-Clemente A , Viola KL , Klein WL . Changes in NMDA receptor subunit 1 and 2B expression in ADDL-treated hippocampal neurons . 2005; 2005 Abstract Viewer/Itinerary Planner Washington, DC: Society for Neuroscience[Online], Program No. 786.17
  41. Snyder EM , Nong Y , Almeida CG , Paul S , Moran T , Choi EY , et al.   Regulation of NMDA receptor trafficking by amyloid-beta . Nat Neurosci . 2005;8(8):1051–1058
  42. Kim HJ , Chae SC , Lee DK , Chromy B , Lee SC , Park YC , et al.   Selective neuronal degeneration induced by soluble oligomeric amyloid beta protein . FASEB J . 2003;17(1):118–120
  43. Nomura I , Kato N , Kita T , Takechi H . Mechanism of impairment of long-term potentiation by amyloid beta is independent of NMDA receptors or voltage-dependent calcium channels in hippocampal CA1 pyramidal neurons . Neurosci Lett . 2005;
  44. Puzzo D , Vitolo O , Trinchese F , Jacob JP , Palmeri A , Arancio O . Amyloid-beta peptide inhibits activation of the nitric oxide/cGMP/cAMP-responsive element-binding protein pathway during hippocampal synaptic plasticity . J Neurosci . 2005;25(29):6887–6897
  45. Klyubin I , Walsh DM , Lemere CA , Cullen WK , Shankar GM , Betts V , et al.   Amyloid beta protein immunotherapy neutralizes Aβ oligomers that disrupt synaptic plasticity in vivo . Nat Med . 2005;11(5):556–561
  46. Walsh DM , Townsend M , Podlisny MB , Shankar GM , Fadeeva JV , Agnaf OE , et al.   Certain inhibitors of synthetic amyloid beta-peptide (Aβ) fibrillogenesis block oligomerization of natural Aβ and thereby rescue long-term potentiation . J Neurosci . 2005;25(10):2455–2462
  47. Trommer BL , Shah C , Yun SH , Gamkrelidze G , Pasternak ES , Blaine SW , et al.   ApoE isoform-specific effects on LTP (Blockade by oligomeric amyloid-beta1-42) . Neurobiol Dis . 2005;18(1):75–82
  48. Klyubin I , Walsh DM , Cullen WK , Fadeeva JV , Anwyl R , Selkoe DJ , et al.   Soluble Arctic amyloid beta protein inhibits hippocampal long-term potentiation in vivo . Eur J Neurosci . 2004;19(10):2839–2846
  49. Wang Q , Walsh DM , Rowan MJ , Selkoe DJ , Anwyl R . Block of long-term potentiation by naturally secreted and synthetic amyloid beta-peptide in hippocampal slices is mediated via activation of the kinases c-Jun N-terminal kinase, cyclin-dependent kinase 5, and p38 mitogen-activated protein kinase as well as metabotropic glutamate receptor type 5 . J Neurosci . 2004;24(13):3370–3378
  50. Vitolo OV , Sant’Angelo A , Costanzo V , Battaglia F , Arancio O , Shelanski M . Amyloid beta -peptide inhibition of the PKA/CREB pathway and long-term potentiation (Reversibility by drugs that enhance cAMP signaling) . Proc Natl Acad Sci U S A . 2002;99(20):13217–13221
  51. Chen QS , Kagan BL , Hirakura Y , Xie CW . Impairment of hippocampal long-term potentiation by Alzheimer amyloid beta-peptides . J Neurosci Res . 2000;60(1):65–72
  52. Costello DA , O’Leary DM , Herron CE . Agonists of peroxisome proliferator-activated receptor-gamma attenuate the Aβ-mediated impairment of LTP in the hippocampus in vitro . Neuropharmacology . 2005;49(3):359–366
  53. Walsh DM , Klyubin I , Fadeeva JV , Cullen WK , Anwyl R , Wolfe MS , et al.   Naturally secreted oligomers of amyloid beta protein potently inhibit hippocampal long-term potentiation in vivo . Nature . 2002;416(6880):535–539
  54. Hardy J , Selkoe DJ . The amyloid hypothesis of Alzheimer’s disease (Progress and problems on the road to therapeutics) . Science . 2002;297(5580):353–356
  55. Klein WL . Cytotoxic intermediates in the fibrillation pathway (Aβ oligomers in Alzheimer’s disease as a case study) . In:  Uversky V editors. Protein misfolding, aggregation, and conformational diseases . New York, NY: Kluwer Academic/Plenum Publishers; 2005;
  56. Conway KA , Lee SJ , Rochet JC , Ding TT , Williamson RE , Lansbury PT . Acceleration of oligomerization, not fibrillization, is a shared property of both alpha-synuclein mutations linked to early-onset Parkinson’s disease (Implications for pathogenesis and therapy) . Proc Natl Acad Sci U S A . 2000;97(2):571–576
  57. Reixach N , Deechongkit S , Jiang X , Kelly JW , Buxbaum JN . Tissue damage in the amyloidoses (Transthyretin monomers and nonnative oligomers are the major cytotoxic species in tissue culture) . Proc Natl Acad Sci U S A . 2004;101(9):2817–2822
  58. Butler AE , Janson J , Soeller WC , Butler PC . Increased beta-cell apoptosis prevents adaptive increase in beta-cell mass in mouse model of type 2 diabetes (Evidence for role of islet amyloid formation rather than direct action of amyloid) . Diabetes . 2003;52(9):2304–2314
  59. Kuo YM , Emmerling MR , Vigo-Pelfrey C , Kasunic TC , Kirkpatrick JB , Murdoch GH , et al.   Water-soluble Aβ (N-40, N-42) oligomers in normal and Alzheimer disease brains . J Biol Chem . 1996;271(8):4077–4081
  60. Frackowiak J , Zoltowska A , Wisniewski HM . Non-fibrillar beta-amyloid protein is associated with smooth muscle cells of vessel walls in Alzheimer disease . J Neuropathol Exp Neurol . 1994;53(6):637–645
  61. Lambert MP , Lacor PN , Chang L , Viola KL , Velasco PT , Richardson DK , et al.   ADDL-generated monoclonal antibodies target epitopes specific to Aβ oligomers . 2003; 2003 Abstract Viewer/Itinerary Planner Washington, DC: Society for Neuroscience[Online], Program No. 527.16
  62. Lambert MP, Velasco PT, Chang L, Viola KL, Fernandez SJ, Lacor PN, et al. Monoclonal antibodies that target pathological assemblies of Aβ. submitted .
  63. Kayed R, Head E, Thompson JL, McIntire TM, Milton SC, Cotman CW, et al. Common structure of soluble amyloid oligomers implies common mechanism of pathogenesis . Science . 2003;300(5618):486–489
  64. Oddo S , Caccamo A , Shepherd JD , Murphy MP , Golde TE , Kayed R , et al.   Triple-transgenic model of Alzheimer’s disease with plaques and tangles (Intracellular Aβ and synaptic dysfunction) . Neuron . 2003;39(3):409–421
  65. Oddo S , Caccamo A , Tram L , Lambert MP , Glabe CG , Klein WL , et al.   Temporal profile of Aβ oligomerization in an in vivo model of Alzheimer’s disease (A link between Aβ and tau pathology) . J Biol Chem . 2006;281(3):1599–1604
  66. Westerman MA , Chang L , Frautschy S , Kotilinek L , Cole G , Klein W , et al.   Ibuprofen reverses memory loss in transgenic mice modeling Alzheimer’s disease . Soc Neurosci Abstr . 2002;28, 690.4:10–15
  67. Mesulam MM . Neuroplasticity failure in Alzheimer’s disease (Bridging the gap between plaques and tangles) . Neuron . 1999;24(3):521–529
  68. Ohno M, Chang L, Tseng W, Oakley H, Citron M, Klein WL, et al. Temporal memory deficits in Alzheimer’s mouse models: Rescue by genetic deletion of BACE1 with reduced amyloid-β oligomers. Eur J Neurosci. In press.
  69. Bigio EH , Lambert MP , Shaw P , Lacor PN , Viola KL , Klein WL . Aβ oligomers in aging and Alzheimer disease . J Neuropathol Exp Neurol . 2005;64(5):440
  70. Takahashi RH , Almeida CG , Kearney PF , Yu F , Lin MT , Milner TA , et al.   Oligomerization of Alzheimer’s beta-amyloid within processes and synapses of cultured neurons and brain . J Neurosci . 2004;24(14):3592–3599
  71. Klunk WE , Engler H , Nordberg A , Wang Y , Blomqvist G , Holt DP , et al.   Imaging brain amyloid in Alzheimer’s disease with Pittsburgh Compound-B . Ann Neurol . 2004;55(3):306–319
  72. Montalto MC, Agdeppa ED, Siclovan TM, Williams AC. Composition and methods for non-invasive imaging of soluble beta-amyloid. New York/USA patent US 2004/0223909 A1. 2004 Nov 2004.
  73. Georganopoulou DG , Chang L , Nam JM , Thaxton CS , Mufson EJ , Klein WL , et al.   Nanoparticle-based detection in cerebral spinal fluid of a soluble pathogenic biomarker for Alzheimer’s disease . Proc Natl Acad Sci U S A . 2005;102(7):2273–2276
  74. Allison DW , Chervin AS , Gelfand VI , Craig AM . Postsynaptic scaffolds of excitatory and inhibitory synapses in hippocampal neurons (maintenance of core components independent of actin filaments and microtubules) . J Neurosci . 2000;20(12):4545–4554
  75. Carlisle HJ , Kennedy MB . Spine architecture and synaptic plasticity . Trends Neurosci . 2005;28(4):182–187
  76. Matsuzaki M , Ellis-Davies GC , Nemoto T , Miyashita Y , Iino M , Kasai H . Dendritic spine geometry is critical for AMPA receptor expression in hippocampal CA1 pyramidal neurons . Nat Neurosci . 2001;4(11):1086–1092
  77. Fiala JC , Spacek J , Harris KM . Dendritic spine pathology (Cause or consequence of neurological disorders?) . Brain Res Brain Res Rev . 2002;39(1):29–54
  78. Calon F , Lim GP , Yang F , Morihara T , Teter B , Ubeda O , et al.   Docosahexaenoic acid protects from dendritic pathology in an Alzheimer’s disease mouse model . Neuron . 2004;43(5):633–645
  79. Horrocks LA , Yeo YK . Health benefits of docosahexaenoic acid (DHA) . Pharmacol Res . 1999;40(3):211–225
  80. Tully AM , Roche HM , Doyle R , Fallon C , Bruce I , Lawlor B , et al.   Low serum cholesteryl ester-docosahexaenoic acid levels in Alzheimer’s disease (A case-control study) . Br J Nutr . 2003;89(4):483–489
  81. Guzowski JF , Lyford GL , Stevenson GD , Houston FP , McGaugh JL , Worley PF , et al.   Inhibition of activity-dependent arc protein expression in the rat hippocampus impairs the maintenance of long-term potentiation and the consolidation of long-term memory . J Neurosci . 2000;20(11):3993–4001
  82. Steward O , Worley P . Local synthesis of proteins at synaptic sites on dendrites (Role in synaptic plasticity and memory consolidation?) . Neurobiol Learn Mem . 2002;78(3):508–527
  83. Guzowski JF . Insights into immediate-early gene function in hippocampal memory consolidation using antisense oligonucleotide and fluorescent imaging approaches . Hippocampus . 2002;12(1):86–104
  84. Kelly MP , Deadwyler SA . Experience-dependent regulation of the immediate-early gene arc differs across brain regions . J Neurosci . 2003;23(16):6443–6451
  85. Rial Verde EM , Worley P , Malinow R , Cline HT . The immediate-early gene Arc regulates AMPA_receptor trafficking . Soc Neurosci Abstr 29 . 2003;55.7:10–15
  86. Palop JJ , Chin J , Bien-Ly N , Massaro C , Yeung BZ , Yu GQ , et al.   Vulnerability of dentate granule cells to disruption of arc expression in human amyloid precursor protein transgenic mice . J Neurosci . 2005;25(42):9686–9693
  87. Mucke L , Masliah E , Yu GQ , Mallory M , Rockenstein EM , Tatsuno G , et al.   High-level neuronal expression of Aβ 1-42 in wild-type human amyloid protein precursor transgenic mice (Synaptotoxicity without plaque formation) . J Neurosci . 2000;20(11):4050–4058
  88. Tong L , Thornton PL , Balazs R , Cotman CW . Beta -amyloid-(1-42) impairs activity-dependent cAMP-response element-binding protein signaling in neurons at concentrations in which cell survival Is not compromised . J Biol Chem . 2001;276(20):17301–17306
  89. Longo VD , Viola KL , Klein WL , Finch CE . Reversible inactivation of superoxide-sensitive aconitase in Aβ1-42-treated neuronal cell lines . J Neurochem . 2000;75(5):1977–1985
  90. Cotman CW , Berchtold NC . Exercise (A behavioral intervention to enhance brain health and plasticity) . Trends Neurosci . 2002;25(6):295–301
  91. Yin Y , Edelman GM , Vanderklish PW . The brain-derived neurotrophic factor enhances synthesis of Arc in synaptoneurosomes . Proc Natl Acad Sci U S A . 2002;99(4):2368–2373
  92. Peres SB , de Moraes SM , Costa CE , Brito LC , Takada J , Andreotti S , et al.   Endurance exercise training increases insulin responsiveness in isolated adipocytes through IRS/PI3-kinase/Akt pathway . J Appl Physiol . 2005;98(3):1037–1043
  93. Selkoe DJ . Normal and abnormal biologyof the beta-amyloid precursor protein . Annu Rev Neurosci . 1994;17:489–517
  94. Pollack SJ , Lewis H . Secretase inhibitors for Alzheimer’s disease (challenges of a promiscuous protease) . Curr Opin Investig Drugs . 2005;6(1):35–47
  95. Ferrer I , Boada RM , Sanchez Guerra ML , Rey MJ , Costa-Jussa F . Neuropathology and pathogenesis of encephalitis following amyloid-beta immunization in Alzheimer’s disease . Brain Pathol . 2004;14(1):11–20
  96. Klein WL , Krafft GA , Finch CE . Targeting small Aβ oligomers (The solution to an Alzheimer’s disease conundrum?) . Trends Neurosci . 2001;24(4):219–224
  97. De Felice FG , Vieira MN , Saraiva LM , Figueroa-Villar JD , Garcia-Abreu J , Liu R , et al.   Targeting the neurotoxic species in Alzheimer’s disease (Inhibitors of Aβ oligomerization) . FASEB J . 2004;18(12):1366–1372
  98. Wang Z , Chang L , Klein WL , Thatcher GR , Venton DL . Per-6-substituted-per-6-deoxy beta-cyclodextrins inhibit the formation of beta-amyloid peptide derived soluble oligomers . J Med Chem . 2004;47(13):3329–3333

PII: S1552-5260(05)00502-9

doi: 10.1016/j.jalz.2005.11.003

Alzheimer's & Dementia: The Journal of the Alzheimer's Association
Volume 2, Issue 1 , Pages 43-55 , January 2006

Article Tools

* Image Usage & Resolution